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cense.Abstract Background and purpose: Neuroblastoma is the most common extracranial and deadly
solid tumor in children. It accounts for 15% of the deaths from cancer in the pediatric age group.
Approximately half of the newly diagnosed children are at ‘‘high risk’’ of treatment failure.
The aim of this study is to evaluate the response rate of salvage chemotherapy by the ICE (Ifosfa-
mide, Carboplatin, and Etoposide) regimen when administered to previously treated primary
refractory or progressive high risk neuroblastoma patients.
Patients and methods: Sixty-six patients from the National Cancer Institute (NCI), Cairo Univer-
sity and the Children Cancer Hospital Egypt (CCHE) received salvage chemotherapy (ICE) either201919.
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Institute, Cairo University.
.
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48 H.A. Rahman et al.due to primary resistance in 51/66 (77.2%) or due to disease progression on primary chemotherapy
in 15/66 (22.8%).
Results: They were 40 males (60.6%) and 26 females (39.4%). Patients’ age ranged between
3 months and 12.5 years. The most common tumor site was suprarenal, followed by retroperitoneal
mass. Two patients (3%) died from chemotherapy toxicity during ICE administration. Evaluation
of tumor response in the remaining 64 patients showed the following: CR/PR in 24 patients
(36.5%), SD in 11 patients (16.6%), and PD in 29 patients (43.9%).
Fourteen patients (21.2%) were considered eligible for auto BMT, while 50/64 patients (78.8%)
failed this second line (salvage) chemotherapy and had palliative lines of therapy.
By the end of the study (May 2010), 47/66 (71.2%) of the patients were still alive, while 19/66
(28.8%) were dead. Two out of 14 patients (14.2%) who underwent HSCT died from post trans-
plantation disease progression, while 12/14 (85.8%) were in CCR.
Conclusion: Chemotherapy by ICE for primary resistant or progressive stage III/IV NB seems well
tolerated. With a 36.6% response rate, 18% CCR, and 3% treatment mortality rate, it could be
considered a good salvage therapy in the category of patients who are condemned for palliation.
ª 2011 National Cancer Institute, Cairo University. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.Introduction
Neuroblastoma (NB) is the most common extracranial and
deadly solid tumor in children. It accounts for 8–10% of child-
hood cancers and 15% of the deaths from cancer in the pedi-
atric age group [1]. Approximately half of the newly diagnosed
children with this tumor will have metastatic disease or histo-
logically aggressive large tumors that are at ‘‘high risk’’ for
treatment failure [2].
Several prognostic factors have been identiﬁed including
age, staging system, but the ampliﬁcation of N-MYC con-
fers a worse prognosis for all neuroblastic tumor groups,
including patients with locoregional tumors or young
infants [3,4].
Approximately 80% of stage IV patients have detectable
marrow involvement. Similarly, patients with multiple bone
metastases had a worse outcome. Overall, patients with
abdominal primaries in particular stages III and IV, have a less
favorable prognosis than those with cervical, pelvic, and tho-
racic primaries [5].
Chemotherapy is still the mainstay treatment for the sys-
temic control of these tumors. Currently, the most common
chemotherapeutic agents utilized are cyclophosphamide,
iphosphamide, vincristine, doxorubicin, cisplatin, Carboplatin,
Etoposide and melphalan [6].
Over the last two decades several new chemotherapeutic
agents with anti-neuroblastoma activity have been studied
including irinotican, topotecan, cyclophosphamide and temo-
zolamide [6]. For advanced-stage tumors, combined chemo-
therapy failed to effectively eradicate the disease; however, it
often reduces the size of the primary tumors of advanced stage,
allowing them to be resectable [7].
Bone marrow-ablative therapy with total body irradiation
or melphalan with subsequent bone marrow transplant
(BMT) has shown to improve event-free survival as compared
to intensive chemotherapy for high-risk neuroblastoma pa-
tients [8,9].
Notwithstanding the intensive treatment, relapse and
refractory disease are frequent and still pose a clinical chal-
lenge, as long-term survival after relapse is virtually unheard
of [10].Current surgery and radiotherapy techniques in conjunc-
tion with induction chemotherapy have greatly reduced the
risk of local relapse. However, in advanced neuroblastoma,
circulating tumor cells were detected in the peripheral blood
by several methods, suggesting that advanced disease is no
longer localized.
The clinical signiﬁcance of intensive surgical therapy as a
means to control the local lesion has been controversial in
the treatment of advanced neuroblastoma to date. Therefore,
the role of extensive surgery with a higher incidence of major
complications was not supported in some reports [11,12], but
emphasized in one study [13].
Total surgical resection with Intra-Operative Radiother-
apy (IORT) is considered to be the most intensive surgical
therapy to control the local malignant lesion, because the
electron beam of IORT is estimated to reach to the depth
of 1 cm into the tissue and eliminate the viable tumor cells
[14,15].
The aim of this study is to evaluate the response rate of sal-
vage chemotherapy by the ICE (Ifosfamide, Carboplatin, and
Etoposide) regimen when administered to previously treated
primary refractory or progressive high risk neuroblastoma
patients.
Patients and methods
Patients with stages III/IV neuroblastoma who were either
primary refractory or progressive on high risk treatment pro-
tocol were included in this study. They were treated at the
Pediatric Oncology Department either at the Egyptian Na-
tional Cancer Institute (NCI), Cairo University, or the Chil-
dren Cancer Hospital Egypt (CCHE) during the period from
July 2007 to December 2009, with a follow up period until
May 2010.
Patients received from 2 to 8 courses of salvage chemother-
apy ICE (Ifosfamide 1.8 g/m2 day 1–5, Carboplatine 450 mg/
m2 day 1 and Etoposide 100 mg/m2 day 1–5) aiming to achieve
CR/PR and, subsequently go to consolidation with intensive
dose chemotherapy and Hematopoietic Stem Cell Transplan-
tation (HSCT).
Did salvage ICE chemotherapy improve the outcome in primary resistant/relapsing stage III/IV neuroblastoma? 49Patient eligibility
A. Patients received high risk induction chemotherapy if
they had:
1. Biopsy-proven neuroblastoma or positively inﬁl-
trated bone marrow.
2. Age of patients less than 18 years at diagnosis.
3. Staging:
 Stage IV patients except those less than 1 year of
age with non-ampliﬁed N-MYC gene.
 Stage III patients with ampliﬁed N-MYC gene.
 Stage III patients with unfavorable Shimada
pathology.4. Adequate hematopoietic, hepatic and renal
functions.Pathology guidelines
Cases were histologically evaluated according to the Interna-
tional Neuroblastoma Pathology Committee, Shimada 1999
taking into consideration age, histologic picture and the Mito-
sis Karyorrhexis index for stratiﬁcation of patients into favor-
able and unfavorable. N-MYC gene status was performed
using Fluorescence In Situ Hybridization (FISH) on parafﬁn
embedded tissue sections.
Deﬁnition of response criteria
Complete response (CR). Complete disappearance of all mea-
surable or evaluable lesions (except bone).
Partial response (PR). Reduction (20–99%) in the product of
the two largest diameters (perpendicular) of measurable lesions.
No response (NR) or stable disease (SD). Tumor reduction
(<20%) of the product of the two largest diameters (perpen-
dicular) of measurable lesions.
Progressive disease (PD).>25% increase in the product of the
two largest diameters (perpendicular) of measurable lesions.
Relapse. Recurrence of disease at any site after achieving a CR.
Primary chemotherapy
Patients received induction chemotherapy with eight cycles of
alternating VP16/CARBO [Etoposide 200 mg/m2 · 3 days
and Carboplatin 500 mg/m2 on day 1] and CADO [cyclo-
phosphamide 300 mg/m2 · 5 days, doxorubicin 60 mg/m2
day 5 and vincristine 1.5 mg/m2 (maximum 2 mg) days 1
and 5].
B. Patients were eligible for salvage ICE chemotherapy if
they had:
Failure of induction chemotherapy as evidenced by either
primary refractory (failure to achieve CR/PR after 4–6 cycles
of Induction chemotherapy), or progressive disease with ade-
quate hematopoietic, hepatic and renal functions.
Patient evaluation
The following work-up was done before starting salvage
chemotherapy:(1) CT scan of the primary tumor and all metastatic sites.
(2) Bilateral bone marrow aspirate and biopsy.
(3) Whole Body Tc99 Bone scan.
(4) MIBG scan (when feasible).
Salvage chemotherapy
Two to eight cycles of ICE were given, aiming to achieve CR/
PR for primary refractory, relapsing, or progressive disease in
NB patients.
Reassessment of tumor response was performed after every
second course by CT/MRI, bone scan, MIBG scan, and BM
biopsy (if previously positive or suspected inﬁltration on
MIBG scanning).
Patients with CR/VGPR were assessed for operability (if
their tumor was not previously resected), followed by HSCT
and involved ﬁeld (IF) radiotherapy. Those with partial re-
sponse or stable disease resumed chemotherapy till they be-
came eligible for HSCT, or reached a maximum of eight
courses. Patients with disease progression were taken off
therapy.
Surgical guidelines
The goal of this surgery was gross total resection of residual
tumor in the primary site as well as tumor in areas of regional
dissemination (usually lymph nodes). Resection with micro-
scopically negative margins may not be feasible because of
proximity to major vascular structures and the spine. Timing
for surgical interference was determined according to tumor
response at different stages of therapy.
Radiotherapy guidelines
Local irradiation was administered to the primary site in pa-
tients after HSCT. The macroscopic tumor volume (GTV)
was deﬁned from post induction chemotherapy scans that
were obtained prior to the time of delayed surgical resection.
The clinical target volume (CTV) was deﬁned as the GTV
plus a 1.5-cm margin. The planning target volume (PTV)
was deﬁned as the CTV plus a 0.5 cm margin. For patients
without evidence of macroscopic residual disease after induc-
tion chemotherapy and surgical resection, a dose of 21.6
grays (GY) was administered in 1.8 Gy fractions per day
5 days a week. Areas of macroscopic residual disease after
surgery received an additional booster dose of 14.4 Gy over
eight fractions, for a total dose of 36.0 Gy. Radiation was
also given to metastatic sites with persistent active disease
on MIBG and/or bone scan demonstrated on the pre-HSCT
evaluation. The planning target volume for metastatic sites is
the area of residual tumor deﬁned on MIBG, CT or MR
scan with a 1 cm margin.
Statistical analysis
SPSS package for Windows, version 15 (SPSS Inc., Chicago,
Illinois, USA) was used. The overall survival was calculated
from the date of diagnosis to the date of death or of last
contact. The functions for overall survival were estimated
using the Kaplan–Meier product limit method [16]. Compar-
ison between two survival times was done by the Log-rank
test. p-Value equal to or less than 0.05 was considered
signiﬁcant.
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Sixty-six patients were eligible for the study. Table 1 shows
patients’ characteristics at presentation.
Patients’ age ranged between 3 months and 12.5 years with
a median of 3.3 years.
According to the International Neuroblastoma Staging
System (INSS), most of the patients were in stage IV. The most
common tumor site was suprarenal.
Following induction chemotherapy, 41/66 patients (62.1%)
had surgical intervention as a form of local therapy, while 25/
66 patients (37.9%) were not eligible for surgical resection
mostly due to tumor irresectability. Twenty patients (30.3%)
received radiotherapy to the primary or metastatic site of the
tumor, 11/66 of them (16.6%) post autologous HSCT, and
9/66 patients (13.6%) on palliative basis. The rest of the pa-
tients (46/66 patients, 70%) were not eligible for radiation
therapy.
Causes of salvage chemotherapy by ICE were either pri-
mary resistant in 51/66 (77.2%) or disease progression in 15/
66 (22.8%).
Two patients (3%) died from chemotherapy toxicity during
ICE administration. Evaluation of tumor response in the
remaining 64 patients at the end of the study [May 2010]
showed the following: CR/PR in 24 patients (36.5%), SD in
11 patients (16.6%), PD in 29 patients (43.9%) by the end of
the chemotherapy course (6 months).
Fourteen patients (21.2%) were considered eligible for
HSCT, while 50/64 patients (78.8%) failed this second line
(salvage) chemotherapy and had palliative lines of therapy.
Patients who underwent HSCT were eight males and six fe-
males. Their ages ranged from 9 months to 9.8 years, and the
median age was 3.4 years. Almost all the patients 13/14
(92.8%) had neuroblastoma while 1/14 (7.2%) patients had
ganglioneuroblastoma. Shimada classiﬁcation was favorable
in 4/14 (28.5%) and unfavorable in 10/14 (71.5%). AccordingTable 1 Patient characteristics at presentation.
Total number (n= 66) Percentage
Sex
Male 40 60.6
Female 26 39.4
Pathology
Favorable 10 15.2
Unfavorable 56 84.8
N-Myc
Ampliﬁed 16 24.2
Nonampliﬁed 23 34.8
Not done 27 40.9
Stage
3 10 15.2
4 56 84.8
Site
Suprarenal 44 66.6
Retroperitoneal 10 15.2
Mediastinal 6 9.1
Other sites 6 9.1
Surgery 41 62.1
Radiotherapy 20 30.3to INSS; 3/14 (21.4%) patients had stage III while 11/14
(78.5%) patients had stage IV disease. Eleven patients
(78.5%) had suprarenal mass, 2/14 (14.3%) had retroperito-
neal mass and 1/14 (7.2%) had a mediastinal mass.
Surgical intervention (either initially or following ICE) was
done for 11/14 (78.5%) while 3/14 (21.4%) patients underwent
HSCT without being operated upon due to tumor irresectabil-
ity. The type of surgery was complete resection in 10/11
(90.9%) and partial resection (debulking) in 1/11 (9.1%). Most
of the good responding patients (12/14 85.7%) were initially
primary resistant while 2/14 (14.2%) received salvage therapy
due to disease progression. ICE cycles given for BMT patients
were of a minimum of two cycles and a maximum of six cycles
(median four cycles).
Post HSCT, 11 patients (78.5%) received a radiation of
21.6 Gy to the operative bed. One patient required an addi-
tional boost dose of 14.4 Gy over eight fractions, for a total
dose of 36.0 Gy. Of the three patients who did not receive radi-
ation, two patients died from post transplantation disease pro-
gression and one patient’s family declined the option to receive
radiation.
By the end of the study (May 2010), 47/66 (71%) of the
patients were still alive, while 19 patients (29%) were dead.
Twelve patients (18%) were in continuous complete remis-
sion (CCR) post HSCT, while 35/66 (53%) were alive in dis-
ease progression under palliative measures.
Two patients (3%) died from chemotherapy [ICE] toxicity,
two of the patients (3%) who underwent HSCT and 15/66
(23%) of the nonresponders died from disease progression.
The median follow up time was 18 months and ranged from
1.4 to 33.2 months. The cumulative overall survival at
33.2 months was 68% (Fig. 1).
The cumulative overall survival stratiﬁed by initial disease
status at 18 months was 65% for those with progressive dis-
ease, while it was 69% for primary resistant patients at the
same time period. This difference was not statistically signiﬁ-
cant (p-value 0.44) (Fig. 2).
When comparing the survival for those who received HSCT
and the rest of the group, cumulative overall survival was 90%
and 60%, respectively at 18 months, but this difference was
not statistically signiﬁcant (p-value 0.06) (Fig. 3).
Discussion
In our study, salvage ICE chemotherapy showed CR/PR re-
sponse of 36.6%, allowing about 21% of the patients to go
for auto HSCT, and about 18% to go into CCR. With mainly
grade IV hematopoietic toxicity, and 3.8% toxic deaths – in
previously heavily treated cancer patients – it seems to be well
tolerated.
ICE chemotherapy has been used with success for resistant
lymphomas and relapsed solid tumors [5], due to the favorable
spectrum of non-hematopoietic toxicity and evidence of syn-
ergy in vitro of these selected drugs.
In advanced and recurrent neuroblastoma, Garaventaa
et al. achieved CR and PR rate of 73% after 1–8 courses of
ICE (median 2) [17].
The camptothecins topotecan [17–19] and irinotecan [20,21]
have proven anti-NB activity and have been extensively used in
salvage regimens. Until recently the combination of cyclophos-
phamide and topotecan was the ﬁrst line salvage regimen
Figure 1 Overall survival for the 66 patients.
Figure 2 Overall survival stratiﬁed by initial status.
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Figure 3 Oiﬁed by BMT status.
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bination into front line therapy in the current COG protocol
for newly diagnosed high-risk NB, it is likely that a further well
studied combination of irinotecan plus temozolomide will be
increasingly utilized for resistant NB [23]. Both combinations
have demonstrated anti-NB utility though CR/VGPR was
rare. Irinotecan was evaluated for efﬁcacy and safety in pedi-
atric recurrent or refractory neuroblastoma with no objective
response in heavily pre-treated children [24].
In our study, patients received from 2 to 8 courses of ICE
(mean 5 and median 3.65). Response rate was 36.6% CR/
PR, 13.6% SD, 43.9% PD, and allowing 21% of the good
responders to undergo HSCT.
Our CR and PR rate are lower than what Kramer et al. [25]
reported in their study to evaluate the role of high dose ICE
therapy for advanced, recurrent NB; for 26 evaluable patients,
they had 6 CRs, 13 PRs, 2 SDs, and 3 PDs with a CR and PR
rate of 73% achieved after 1–8 courses of ICE (median 2), and
six responders went onto BMT. They concluded that high dose
ICE is an effective, fast acting remission induction therapy for
patients with advanced recurrent neuroblastoma. This might
be due to the dose of Carboplatine ICE which was escalated
in Kramer’s study [25].
At Memorial Sloan Kettering Cancer Center (MSKCC),
camptothecins are combined with high-dose cyclophospha-
mide both for anti-NB effect and to permit the administration
of the murine antibody 3F8 for consolidation in case of re-
sponse to chemotherapy [26]. Other new chemotherapeutic
agents with potential anti-NB activity include ABT-751, an
oral anti-tubulin agent, though no complete or partial re-
sponses were observed in the initial phase I study [18].
In our study, patients who achieved CR/PR and went into
auto HSCT are those who had favorable Shimada pathology,
stage III initial tumor, suprarenal mass and more surgical
resection in comparison to the total number of patients(Table 1). Similarly, ‘‘The Italian Neuroblastoma Registry’’
investigated and detected a better overall survival (OS) after
progression and relapse for age at diagnosis <18 months, less
advanced International Neuroblastoma Staging System
(INSS) stage, normal lactate dehydrogenase (LDH) serum le-
vel, normal N-MYC gene status (p< 0.001) and a non-
abdominal primary site. A local type of recurrence had a sig-
niﬁcantly better outcome only in case of relapse [17].
Conclusion
Chemotherapy by ICE for primary resistant or progressive
stage III/IV NB seems well tolerated. With a 36.6% response
rate and an 18% CCR, ICE could be considered a good sal-
vage therapy in a category of patients who are condemned
for palliation.References
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